雌激醇通过雌激素受体-α,但不是通过雌激素受体-β加速小鼠动脉中的再内皮化
L Brouchet1, A Krust, S Dupont
1INSERM U397, Institut L. Bugnard, CHU Rangueil, Toulouse, France.
Circulation
|February 7, 2001
概括
17β-雌二醇 (E(2)) 加快了再内化,这是预防动脉样硬化的关键过程. 这种有益的效果是由雌激素受体-alpha (ERalpha) 而不是ERbeta在小鼠中介导的.
科学领域:
- 心血管生物学 心血管生物学
- 内分泌学 在内分泌学.
- 血管生物学 血管生物学
背景情况:
- 17β-雌二醇 (E(2)) 在女性和动物身上表现出有氧保护作用.
- ) 影响脂质代谢,并直接影响动脉壁细胞.
- 研究表明,E(2) 增强内皮依赖性放松和再内皮化.
研究的目的:
- 在小鼠中研究E(2) 介导的重新内皮质化分子机制.
- 评估雌激素受体 (ERalpha和ERbeta) 在E(2) 对血管修复的影响中的作用.
主要方法:
- 在小鼠中开发了一种电动动脉损伤模型,以评估再内皮质化.
- 使用割的野生型雌性小鼠和经过卵巢切除的缺乏ERalpha或ERbeta的转基因小鼠.
- 管理E(2) 评估其对内皮再生的影响.
主要成果:
- 在野生型小鼠中显著加快了内皮再生.
- 在ERbeta淘汰赛小鼠中,E(2) 促进了reendothelialization.
- 在ERalpha淘汰赛小鼠中,E(2) 的亲再生作用被废除了.
结论:
- 雌激素受体-α (ERalpha) 是E(2) 对重新内皮质化有益作用的主要媒介.
- 埃拉尔法在潜在的动脉样硬化的预防中起着至关重要的作用.
- 埃尔贝塔似乎没有调解E(2) 对重新内皮质化的影响.
相关概念视频
Adrenergic Agonists: Direct-Acting Agents
2.8K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
2.8K
Adrenergic Agonists: Indirect-Acting Agents
2.8K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.8K
Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.4K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K
Antihypertensive Drugs: Vasodilators
2.5K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.5K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
2.1K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
2.1K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
619
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
619


